Browsing by Author "Sargın, Fatma Deniz"
Now showing items 1-3 of 3
-
HLA-A allele mismatch (7/8 or 9/10) is the second best option after 8/8 or 10/10 matched unrelated donors: An analysis on results from Turkish centers
Beksaç, Meral; Savran Oğuz, Fatma; Topçuoğlu, Pervin; Karasu, Gülsun; Arat, Mutlu; Aksoylar, Serap; Kansoy, Savaş; Kalayoğlu Beşışık, Sevgi; Küpesiz, Alphan; Hazar, Volkan; Altuntaş, Fevzi; Ünal, Ali; Gülbaş, Zafer; Sargın, Fatma Deniz; İlhan, Osman; Gürman, Günhan; Yeşilipek, Akif (Nature Publishing Group, 2015)Introduction: Hematopoietic stem cell transplantation (HSCT) from an unrelated donor has been established as an effective treatment option for patients with hematological diseases who lack a human leukocyte antigen ... -
Miyeloproliferatif neoplazilerde moleküler olayların önemi
Hindilerden, İpek Yonal; Hindilerden, Fehmi; Sargın, Fatma Deniz (İstanbul Üniversitesi, 2015)Kronik miyeloproliferatif neoplaziler (MPN), hematopoetik kök hücreden köken alan, bir veya daha fazla miyeloid serinin anormal proliferasyonu ile karakterize hematopoetik sistemin klonal bir grup hastalığıdır. ... -
A real-life Turkish experience of venetoclax treatment in high-risk myelodysplastic syndrome and acute myeloid leukemia
Gemici, Aliihsan; Özkalemkaş, Fahir; Doğu, Mehmet Hilmi; Tekinalp, Atakan; Alacacıoğlu, İnci; Güney, Tekin; İnce, İdris; Gedük, Ayfer; Akgün Çağlıyan, Gülsüm; Maral, Senem; Serin, İstemi; Gündüz, Eren; Karakuş, Volkan; Beköz, Hüseyin Saffet; Eren, Rafet; Pınar, İbrahim Ethem; Güneş, Ahmet Kürşad; Sargın, Fatma Deniz; Sevindik, Ömür Gökmen (CIG Media Group, 2021)Venetoclax is a selective B-cell lymphoma 2 (BCL2) inhibitor, which is approved to treat elderly patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). A total of 60 patients ...
